Eisai and Arena Pharmaceuticals have announced that a pooled analysis of the BLOOM and BLOSSOM pivotal, Phase III clinical trials...
The purpose of the study is to test the effect of Sitagliptin on the healing of stable, nonhealing diabetic foot...
A new comparative effectiveness analysis, published online in Wound Repair & Regeneration, reported that Apligraf, from Novartis, has demonstrated improved...
Vanda Pharmaceuticals Inc. announced the results from its Phase III study of tradipitant in motion sickness, confirming the previously reported results demonstrating that tradipitant is effective in the prevention of vomiting associated with motion sickness
HOPE study demonstrates that local inflammation is a suitable target for treatment in patients with debilitating disease1